DrugBiological
Tremelimumab clinical trials
Also written CP-675,206, CP-675206, Ticilimumab and Imjudo.
- studies test it
- 185
- open now
- 25
- in phase 3
- 19
- first study started
- 2003
Keep track of what changes. Save the tremelimumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
185 studies that test it; most in 2017 (32)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 9 |
| 2015 | 15 |
| 2016 | 20 |
| 2017 | 32 |
| 2018 | 30 |
| 2019 | 11 |
| 2020 | 8 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 8 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 65
- Phase 2
- 117
- Phase 3
- 19
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 11
Who runs them
Industry 47 · Other 138
AstraZeneca (34) · M.D. Anderson Cancer Center (9) · MedImmune LLC (9) · Canadian Cancer Trials Group (6) · Memorial Sloan Kettering Cancer Center (5) · Ludwig Institute for Cancer Research (5) · Jonsson Comprehensive Cancer Center (4) · Seoul National University Hospital (4)
Often tested with
Tested in the same studies.
Durvalumab (126) · Cisplatin (6) · Paclitaxel (5) · Olaparib (5) · Carboplatin (4) · Gemcitabine (4) · Bevacizumab (3) · Docetaxel (3)
Studies
Open first, then newest update. How each study uses tremelimumab is read from its arms, and is right about nine times in ten.
Testing it · 185
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034Written as Tremelimumab
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingPhase 3AstraZenecaNCT06921785Written as Tremelimumab
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225Written as Tremelimumab
- Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingPhase 2Chang Gung Memorial HospitalNCT06999707Written as Tremelimumab
- Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingPhase 2Chang Gung Memorial HospitalNCT06999694Written as Tremelimumab
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingPhase 3Stanford UniversityNCT04585490Written as Tremelimumab
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Tremelimumab
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Durvalumab + Tremelimumab
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingEarly Phase 1University of California, IrvineNCT06824363Written as Tremelimumab
- Single cEll pRofiling PErsistaNce To ImmuNothErapyRecruitingPhase 2Vall d'Hebron Institute of OncologyNCT06680739Written as Tremelimumab
- Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingPhase 1Mayo ClinicNCT06058663Written as Tremelimumab
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06564623Written as Tremelimumab
- Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisRecruitingPhase 2Center Eugene MarquisNCT07122089Written as Tremelimumab
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2OHSU Knight Cancer InstituteNCT07511504Written as Tremelimumab
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingPhase 2Georgetown UniversityNCT04499053Written as Tremelimumab
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingPhase 2Emory UniversityNCT07174570Written as Tremelimumab
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingPhase 1/2Anwaar SaeedNCT03539822Written as Tremelimumab
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingPhase 2The University of Texas Health Science Center at San AntonioNCT06526104Written as Tremelimumab
- Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingPhase 2Mary Feng, MDNCT04430452Written as Tremelimumab
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingPhase 2Anwaar SaeedNCT06698250Written as Tremelimumab
See all 185 studies that test tremelimumab →
Given in every arm · 29 — tremelimumab is usual care beside what is tested
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Tremelimumab
- A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingPhase 1AstraZenecaNCT07391670Written as Tremelimumab
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingPhase 3NRG OncologyNCT07166406Written as Tremelimumab
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaRecruitingPhase 2/3UNICANCERNCT06904170Written as Durvalumab Plus Tremelimumab
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)RecruitingPhase 2AHS Cancer Control AlbertaNCT05451043Written as Tremelimumab
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03937830Written as Tremelimumab
- Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLCActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT03057106Written as Tremelimumab
- SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruitingPhase 1Jiping Wang, MD, PhDNCT05701488Written as Tremelimumab
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02888743Written as Tremelimumab
- Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCCActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT04522544Written as Tremelimumab
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedPhase 1/2AstraZenecaNCT02499328Written as tremelimumab (treme)
- ......SMARTEST Trial......CompletedPhase 2University Health Network, TorontoNCT05380713Written as Tremelimumab
- Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer PatientsCompletedPhase 1Massachusetts General HospitalNCT03019003Written as Tremelimumab
- Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerCompletedPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT05239169Written as Tremelimumab
- Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedPhase 1/2The Netherlands Cancer InstituteNCT03871036Written as Tremelimumab
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedPhase 2Queen Mary University of LondonNCT02819596Written as Tremelimumab
- A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)TerminatedPhase 1PfizerNCT02616185Written as Tremelimumab
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT03206073Written as Tremelimumab
- A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedPhase 2National Cancer Institute (NCI)NCT02821754Written as Tremelimumab
- A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)Status unknownPhase 2National Cancer Institute, NaplesNCT03975114Written as Tremelimumab
Showing 20 of 29.
As the comparator · 4 — what is tested is compared with tremelimumab
- A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruitingPhase 2Canadian Cancer Trials GroupNCT03847649Written as Tremelimumab
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272Written as Tremelimumab
- Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Status unknownPhase 2Yonsei UniversityNCT03737968Written as durvalumab + tremelimumab
- MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural MesotheliomaCompletedPhase 2Baylor College of MedicineNCT02592551Written as Tremelimumab
Codes
What other systems call tremelimumab · ClinicalTrials.gg INT005105
- MeSH (NLM) C520704tremelimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QEN1X95CIXTREMELIMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2619313One source FDA
- Wikidata Q7838098tremelimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49085TremelimumabOne source FDA
- DrugBank DB11771One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520704 | tremelimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QEN1X95CIX | TREMELIMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2619313 | — | One source FDA |
| Wikidata | Q7838098 | tremelimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49085 | Tremelimumab | One source FDA |
| DrugBank | DB11771 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.